Short-term versus longer term pimozide therapy in Tourette's syndrome: a preliminary study.

The authors randomized 10 patients (age range, 7 to 13 years) with Tourette's syndrome who had achieved a stable level of tic control on open-label pimozide to continue on pimozide (n = 6) or be withdrawn from therapy (n = 4) in a double-blind study. The median time to end point (the time when an increased dose of study medication was required to control tics) was 231 days (continued) versus 37 days (withdrawn), and the survival curves were significantly different (p = 0.02). Chronic, longer term treatment with pimozide appears to be more effective in controlling the course of tics than using the drug acutely to treat an exacerbation.
JournalNeurology (Neurology) Vol. 52 Issue 4 Pg. 874-7 (Mar 10 1999) ISSN: 0028-3878 [Print] UNITED STATES
PMID10078748 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Pimozide
  • Adolescent
  • Child
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Pilot Projects
  • Pimozide (therapeutic use)
  • Prospective Studies
  • Time Factors
  • Tourette Syndrome (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: